Showing posts with label Opioid. Show all posts
Showing posts with label Opioid. Show all posts

Friday, August 18, 2017

Anti Opioid Measures Affect Genuine Pain Sufferers


Today's post from the always excellent pain-topics.org (see link below) talks about the current political hysteria concerning opioids and opioid abuse across the world. True there are recreational users who abuse both the drugs and the system but there are also so many neuropathy and other non-cancer pain sufferers who depend on these drugs to get by each day. Authorities in many lands are introducing stringent measures to control opioid abuse but innocent people are being caught up in the backlash and being denied the drugs they need and deserve. You can almost understand the motives behind this when talking about drug abuse but if the reason also involves money, as is suggested here in Australia, then it is clearly unacceptable to chronic pain sufferers. A very interesting article.


Opiophobia Alive & Well in Oz
Posted by SB. Leavitt, MA, PhD Thursday, January 24, 2013

With all the recent ruckus over prescription opioids and sensational news headlines in the American press inciting fears of these medications, it is easy to believe that the United States is the only country facing such challenges. Apparently, the news is even worse from “down under” in Australia.

According to a brief news item — by Renee Viellaris and appearing in The Australian on January 19, 2013 [here] — physicians will “begin weaning some patients off pain medication as the nation's insatiable habit of pill popping has left health and law enforcement agencies buckling under pressure.” New pharmaceutical guidelines, to be presented this year to state and federal health ministers, will disallow prescribing some patients with “highly addictive and popular pain pills.”

The news report claims that the move has been prompted by the financial drain on the federally-funded Pharmaceutical Benefits Scheme (PBS) from excessive analgesic prescribing, misuse of the medicines, and “research showing long-term use of opioids is counterproductive.” Based on 2010 figures from the Australian National Centre for Education and Training on Addiction (NCETA), in that single year demand for subsidized prescriptions for two types of popular analgesics — oxycodone and fentanyl — cost taxpayers an extra $18 million [$18.9 million USD].

Dr. Steve Hambleton, federal president of the Australian Medical Association, confirmed that “some patients with noncancer pain would have to be weaned off the drugs because they were too expensive and were no longer clinically appropriate. Patients with long-term back or hip pain and those with sporting injuries who take the popular drugs face being directed to alternative therapies, including yoga.”

Hambleton called for more money from government to set up chronic pain clinics in hospitals, but conceded that the new regulations will dramatically change how pain is treated, and at a time when policy makers are also coping with an ageing population. “Some patients will have to be weaned off (and will have to do) things like physical therapy and focus on what you can do and not what you can't — more of a positive attitude,” he said in the news article.

The news report concludes that, “Research provided by NCETA shows that the per capita amount of morphine-equivalent drugs Australians are taking has exploded in the past 30 years.” Furthermore, “the number of Queenslanders on opioid dependence programs is dramatically increasing.”

COMMENTARY: The news report, brief as it is, tells a grim story of what may lie ahead for patients with chronic pain in Oz. And, unfortunately, this is not unlike what is occurring or may happen in other parts of the world, including the U.S.

Our quick scan of the websites of Australian organizations — Chronic Pain Australia serving patients/advocates, and the Australian Pain Society serving healthcare professionals — found no mention of these dire developments. Among other concerns, it would be interesting to know of what research evidence authorities are examining that proves the long-term use of opioid analgesics is “counterproductive.”

The news article notes that the number of persons in Queensland entering opioid-dependence treatment programs has been “dramatically increasing.” However, an accompanying chart shows the rise was only 19% — from roughly 4,900 to 5,800 persons — during the 5-year span 2008 to 2012. It does not say what proportion was attributable to prescription opioid abuse/addiction, or whether this was actually a favorable trend suggesting that more persons with substance-use problems are seeking and getting much needed care. [The U.S. CDC had presented some time ago similarly puzzling data on treatment-program admissions, discussed in an UPDATE here.]

Saving money on federally-funded prescription plans may seem like a worthwhile goal, but we wonder if authorities have considered the unintended consequences — financial and otherwise — of leaving large populations adrift to suffer chronic pain. It seems rather cavalier to suggest that these patients should adopt more positive attitudes and participate in alternative therapies, like yoga, since such interventions only work if they can get out of bed and move nimbly about without adequate pain-relieving medication.

http://updates.pain-topics.org/2013/01/opiophobia-alive-well-in-oz.html

Tuesday, August 15, 2017

Responsible Opioid Prescription For Neuropathy Pain


Today's post from updates.pain-topics.org (see link below) talks about something that many neuropathy patients have issues with and that's the effects of long-term opioid use. Unfortunately, for many people with neuropathy, the pain is just too great to be able to function normally. All of the usual medication options have been tried and have failed and the only possible pain control left is opioids. The problem is their addictiveness and the fact that some of the general population have taken to using them recreationally. Whatever the outcome of various debates around this subject; if you take opioids you need to know that someone qualified is monitoring your progress so that addiction problems can be minimised but for many people, not taking them is not an option.


Opioids on Trial, But Where’s the Evidence?
Wednesday, August 8, 2012

A recent Citizen Petition to the United States Food and Drug Administration (FDA) by Physicians for Responsible Opioid Prescribing, or PROP, requests labeling changes for all opioid analgesics when it comes to their prescription for noncancer pain. The changes would limit the dose, impose time limits, and restrict opioid use for only severe pain.

The Petition raises some important questions about the safety and efficacy of opioid analgesics as they are currently FDA-approved and prescribed. And, the urgency of an investigation was heightened by the fact that a Congressional committee has joined the petitioners in demanding action from the FDA. But, a critical question is whether there is sufficient evidence of reasonable quality for the FDA to act on the Petition at this time.

A Crisis of Confidence in Evidence
At every turn these days, opioid analgesics seem to be on trial, whether in the court of public opinion fueled by mass media, in the U.S. Congress and state legislatures, in various government agencies, and among select groups of healthcare professionals. Yet, what may be most at stake here is a crisis of confidence in scientific methods of inquiry and the reliance on valid research evidence as proof when it comes to making judgments that guide clinical practice in pain management.

Since our inception in late 2005, the mission of Pain Treatment Topics has been to focus on principles of evidence-based pain management. In Part 11 of our ongoing series, “Making Sense of Pain Research”, we examined several questions: What qualifies as evidence? What are the requirements of evidence as proof? How much proof is necessary for reaching valid and just clinical decisions?

We reminded readers, “Just as juries need good evidence to reach prudent verdicts, healthcare providers need good evidence as a guide for better decision-making in treating patients with pain.” However, due to the nature of scientific inquiry and research methods, absolute certainty is an illusion and research outcomes must be used circumspectly and wisely for reaching judicious conclusions affecting patients’ health and well-being.

We say all of this because, as much as anything, the PROP Petition  raises questions about how pain research evidence could and should be interpreted and used for influencing decision-making and change. And, it also raises questions regarding the quality, quantity, relevance, and validity of evidence necessary for establishing an acceptable level of proof in pain management.

In previous UPDATES, we have dissected, discussed, and/or challenged much of the evidence that is used in the PROP Petition to support their requested changes to opioid-product labeling. This and additional evidence also is discussed in a recent guest author UPDATE  by Bob Twillman, PhD, FAPM, and further opinions debating claims of the Petition are offered elsewhere by clinical pharmacy specialist, Jeffrey Fudin, RPh, PharmD, DAAPM, FCCP

In short, there does not appear to be a body of good, clear, and convincing evidence at this time to support the requests in the Petition, let alone any evidence beyond reasonable doubt for passing judgment. However, this is not to say that the petitioners’ assertions are frivolous or unworthy of further investigation and discussion.
In fact, the FDA has posted the Petition at the U.S. government site — www.Regulations.gov — and is accepting public commentary. The URL link is: http://www.regulations.gov/#!documentDetail;D=FDA-2012-P-0818-0001
Document Name: Physicians for Responsible Opioid Prescribing - Citizen Petition
Document ID: FDA-2012-P-0818-0001
Docket ID: FDA-2012-P-0818
We should note that commenting is not limited to Americans, and persons from all parts of the world may have much at stake here. Changes to opioid labeling and prescribing in the U.S. may inspire other countries to re-examine how these medications should best be prescribed in their own populations. We would encourage any and all persons with something to say on this matter, pro or con, to submit a comment.

Here is the text of the public comment letter that we submitted to the FDA on August 6, 2012; Tracking ID# 810c2f4b….
+++++++++++++++++++++++++++++++++++++++++++++++++++++++
TO: FDA Docket ID: FDA-2012-P-0818 at www.Regulations.gov
RE: Physicians for Responsible Opioid Prescribing - Citizen Petition
FR: Stewart B. Leavitt, MA, PhD, on behalf of
Pain Treatment Topics
On July 25, 2012, Physicians for Responsible Opioid Prescribing (PROP) and allied signatories submitted a Citizen Petition to the U.S. Food and Drug Administration (FDA) requesting certain changes to opioid analgesic labeling. These would limit opioid dosing, impose time limits, and restrict opioid use in noncancer conditions to only severe pain.

The Petition appears to be most concerned with opioid analgesia for chronic noncancer pain, and excludes cancer-related pain, but there is some confusion as to whether the label changes would apply also to acute pain. In any event, it seems that the broad and implicit hypothesis underlying the Petition might be stated as this:
Compared with opioid analgesic prescribing practices following indications on current product labeling, patients would be afforded superior effectiveness and safety if opioids were restricted to a dose of ≤100 mg/day of morphine or its equivalent for no more than 90 continuous days and only for severe pain in the case of noncancer conditions.
If this hypothesis is true, countless patients are possibly being mistreated or harmed by current prescribing practices, and it would be important to know if any or all of the Petition’s recommendations should be adopted. As it presently stands, however, there are some serious concerns regarding acceptance of the Petition and its implicit hypothesis:
  • The hypothesis has not been directly tested by adequate, prospective clinical research trials of any quality or sufficient quantity.
  • Current best evidence submitted by the petitioners under their “Statements of Scientific Basis for Petition” has been challenged in terms of its relevance, adequacy, and/or validity [Twillman 2012, ref below].
  • Limited clinical evidence presented at a recent FDA-sponsored Workshop last May, 2012, to assess analgesia for chronic pain was largely of lower quality — observational or epidemiological — and generally equivocal or inconclusive regarding the absolute benefits vs risks of long-term opioid therapy at any dose for various types of pain conditions [FDA 2012].
Therefore, the Petition proposes a hypothesis that raises important questions but, in itself, is untested and unproven. And, it seems apparent that, at this time, changing opioid-product labeling in accordance with the Petition’s requests could be tantamount to enrolling millions of persons with pain — unknowingly and non-consenting — as participants in a clinical experiment to test an unfounded medical theory.

Certainly, the clinical, scientific, ethical, and legal implications of this are daunting, and memory of egregiously cruel human experiments in history would seem to preclude the labeling change at present. Unintended consequences of the label change could possibly be significantly adverse and harsh.

Still, in the court of scientific inquiry there seems sufficient evidence for reasonable suspicion that some, if not all, of the Petition’s perspectives could merit further investigation. Government research-oriented agencies might be encouraged to examine these issues further and to fund the necessary well-designed clinical investigations.
First, however, it would be necessary to operationally define what is specifically meant in the Petition by such terms as: safety, effectiveness, noncancer, and severe pain. And, to better justify for testing the assignation of ≤100 mg/day morphine or equivalent and 90 days duration as threshold points.

Surely, opioid analgesics are not the only or best solution for all types of pain, whether acute or chronic, cancer or noncancer, and in all patients. Ultimately, the goal is to afford patients the best possible pain management, and to identify those patients who might benefit most from opioid analgesia at any dose and/or for any length of time.

References:
> Twillman R. Group Petitions FDA to Change Opioid Label. Pain-Topics UPDATES. 2012(Aug 2); available online at:
http://updates.pain-topics.org/2012/08/group-petitions-fda-to-change-opioid.html
> FDA (U.S. Food and Drug Administration). Assessment of Analgesic Treatment of Chronic Pain: A Scientific Workshop. 2012(May); available at: http://www.fda.gov/downloads/Drugs/NewsEvents/UCM309444.pdf

+++++++++++++++++++++++++++++++++++++++++++++++++++++++
Our purpose in commenting was not to challenge particular research referenced in the Petition or the specifically requested changes; rather, to address issues of scientific method and the uses of evidence as proof. Quite simply, a new clinical hypothesis requires some basis in science or prior evidence to justify testing — which might be met by the limited evidence cited in the Petition — but the hypothesis itself should not be not put into practice until it has been tested and proven valid. Essentially, if opioid labeling were changed at this time in accordance with the Petition it would be “putting the cart before the horse” from an evidence-based medicine perspective.
In his recent guest author Pain-Topics UPDATE, Dr. Twillman, PhD, FAPM, did a thorough job of discussing and questioning the evidence base behind the Petition. In fair balance, immediately after we posted the Twillman UPDATE, we alerted Andrew Kolodny, MD, of the article; he is president of PROP and a principal signer of the Petition. We extended to Dr. Kolodny, and any fellow cosigners of the Petition, an open invitation to submit for publication a rebuttal UPDATE article commenting on Twillman’s critique and/or further presenting their own perspectives. [ADDENDUM: Dr. Kolodny did respond to us later today:

Congress Embraces the Petition
US CongressOn July 26, 2012 — just one day after the Petition was filed with the FDA — Congresswoman Mary Bono Mack and 5 fellow members of the Congressional Caucus on Prescription Drug Abuse sent a public letter  to Margaret Hamburg, MD, FDA Commissioner, essentially endorsing the Petition and embracing all of its recommended labeling changes. The letter concludes:
“We believe that if a labeling change were made to opioid analgesics to reflect the uncertainty and lack of evidence surrounding safety and effectiveness of these drugs for treatment of chronic non-cancer pain, physicians would think twice before prescribing these highly addictive narcotics for ‘moderate’ pain such as a toothache or sore knee. While those who seek treatment for cancer pain and other diseases that cause “severe” pain would not be affected, the number of individuals prescribed opiate painkillers without evidence of the long-term safety and effectiveness may decrease and limit those susceptible to developing opioid dependence.”
To our knowledge, none of these elected officials has extensive medical training or expertise in the assessment of research evidence. Their statement reflects some bias in the use of emotion-laden terms — eg, “highly addictive narcotics” and “painkillers” [discussed previously in an UPDATE  — and, they appear to advocate against even the short-term use of opioids for acute pain, such as a toothache, which is an unclear aspect of the Petition. The Caucus members also seem to have accepted the false argument of the petition, that a lack of evidence is, in itself, acceptable evidence for advocating against the long-term effectiveness and safety of opioids for noncancer pain.
Still, this letter commands the attention of the FDA, since it ends with, “For these reasons, we request an expedited review of the Citizen Petition submitted to FDA, and look forward to a timely response.”

What Happens Now?
FDAIn fairness, the letter from Congresswoman Mack and colleagues was merely instructing the FDA to look into the matter and report back. The FDA already held a Workshop last May exploring analgesia for chronic pain, but this letter probably motivated the agency to accept and post the Petition at the government regulations website on July 30, 2012, for further public comment. Again, that site can be accessed .
We have from time to time been critical of the FDA; yet, we know that the agency performs a vital function and is staffed with well-trained and dedicated physicians and scientists. They understand the ins and outs of pain research and are unlikely to be swayed by low-quality, biased, or inadequate evidence.
In our opinion, there is more at stake here than the fate of opioid analgesics prescribed for chronic noncancer pain. Conflicts of dogma versus science are at the core of many practices in the pain management field; yet, low-quality evidence and fallacies of logical thinking sometimes appear to be winning the battle.
Furthermore, some of the nuances and ramifications of the petitioned label change must be considered:
  • Some have argued that changing the label would stop pharmaceutical companies from promoting opioids for uses beyond the new, more limited indications, but, if deemed necessary, practitioners could still prescribe the medications off-label at any dose and for any duration of time in noncancer pain.

    However, off-label applications of medications are usually discouraged and can be risky; prescribers know that they could face regulatory scrutiny or liability issues if something goes wrong and they have not followed FDA-approved indications on labeling. The Congressional Caucus members are aware of this when they state, “…physicians would think twice before prescribing these highly addictive narcotics.”      
  • This further raises the question of addiction to opioid analgesics among legitimate patients with pain. Evidence regarding this is discussed by Twillman in his UPDATE, and this still appears to be an unresolved issue needing further definition, investigation, and clarification. Yet, the Caucus members seem to accept the notion that restricting opioid prescribing, “may decrease and limit those susceptible to developing opioid dependence.” By dependence, we presume they mean “addiction” here, rather than the physiological dependence on opioids that naturally develops in many cases; although, whether or not they fully understand the distinctions seems unknown.      
  • In reaction to the Petition, some professionals have questioned whether public and private healthcare insurance plans would continue to pay for opioid prescriptions that did not adhere to new restrictions indicated on labeling. If not, patients with chronic pain would need to personally absorb the financial burden associated with off-label opioid prescribing, which in many or most cases could preclude or curtail their ongoing access to these medications. Any answers to insurance coverage questions at this time would be speculative.     
  • Most worrying are questions not even raised and addressed in the Petition or by Congressional Caucus members. What should take the place of opioid analgesics for chronic noncancer pain? What are the better, safer, tried and proven therapies?
There are no easy answers to questions and evidentiary dilemmas posed by the Petition. Our own recommendation is that, if the Petition is to be serously considered and judged, there first must be an objectively thorough review and critical assessment of all relevant evidence regarding this issue — pro and con. And, hopefully, these inquiries and further dialogue will be fair-balanced and steered by science — embracing principles of evidence-based medicine — rather than driven by dogma and demagoguery.

http://updates.pain-topics.org/2012/08/opioids-on-trial-but-wheres-evidence.html

Wednesday, August 9, 2017

An Opioid Without Side Effects For Nerve Pain Is That Possible


Today's post is from genengnews.com (see link below). Don't you just love reading an article that contains a sentence like: “Unlike the conventional opioid fentanyl, this agonist showed pH-sensitive binding, heterotrimeric guanine nucleotide–binding protein (G protein) subunit dissociation by fluorescence resonance energy transfer, and adenosine 3′,5′-monophosphate inhibition in vitro.”!! However, with this sort of text, you have to remember that the ordinary neuropathy patient is essentially not the target audience here and this sort of article needs to be read with a sort of 'skim' technique that gives you the gist of what's being said, while skipping over the techno-speak. The article talks about a new form of opioid that is being developed that does the pain-killing job very effectively but doesn't have the side-effects that the media and politicians just can't cope with at the moment. We have to applaud research in the opioid field that doesn't begin with a skull and crossbones declaration that 'all opioids are bad'. Here they are genuinely recognising the benefits of opioids while trying to eliminate the potential harmful side effects. The whole world seems to be searching for opioid alternatives at the moment (powerful lobby - the anti-opioidals!) when the logical thing to search for is opioid adaptations that make them more user-friendly. Worth a read - you'll get the message I promise you.

Opioid Acts Only on Hurt Tissues, Skips Side Effects 
March 6, 2017 Gen News Highlights

  A new opioid can target “disease-specific” (pathological rather than physiological) conformations of receptors and ligands by selectively activating opioid receptors where acidic conditions prevail, as in tissues affected by inflammation or injury. Thus, the opioid brings pain relief at the site of inflammation and does not affect healthy tissues, such as those of the brain or intestinal wall, thereby avoiding side effects. [G. Del Vecchio & V. Spahn/Freepik]

Opioids, like sledgehammers, are powerful but blunt tools. When they are used to flatten pain, opioids may give other things a pounding, too. The problem is conventional opioids act on inflamed or damaged tissues as well as healthy tissues. Consequently, while opioids may relieve pain, they may also cause serious side effects, such as drowsiness, nausea, constipation, and dependency—and in some cases, respiratory arrest.

In hopes of finding a way to craft finer painkilling tools, scientists based at Charité-Universitätsmedizin Berlin scrutinized different ways opioids can interact with opioid receptors. These scientists, led by Prof. Dr. Christoph Stein, were on the lookout for “disease-specific” opioid receptor-ligand conformations. That is, the scientists plan was to exploit pathological (rather than physiological) conformation dynamics in the design of new opioids, and thereby create drugs that would target damaged or inflamed tissues yet bypass healthy tissues.

"By analyzing drug–opioid receptor interactions in damaged tissues, as opposed to healthy tissues, we were hoping to provide useful information for the design of new painkillers without harmful side effects," said Prof. Dr. Stein.

Prof. Dr. Stein’s team was aware that previous strategies in drug development had focused on central opioid receptors in noninjured environments, even though many painful syndromes (such as arthritis, neuropathy, and surgery) are driven by peripheral sensory neurons and are typically accompanied by inflammation with tissue acidosis. Ultimately, the team decided that this alternative mechanism of action—the binding and activation of peripheral opioid receptors—could be preferentially exploited by a new class of opioids. The key was the occurrence of acid conditions.

By following through on this idea, the scientists designed a new opioid that, unlike clinically used opioids, best activates the receptors in acidified tissues. When the new opioid was evaluated in a rat model of inflammatory pain, it exerted strong pain relief essentially without the side effects of standard opioids.

Details appeared March 3 in the journal Science, in an article entitled, “A Nontoxic Pain Killer Designed by Modeling of Pathological Receptor Conformations.” The article describes how the scientists used computer modeling to analyze morphine-like molecules and their interactions with opioid receptors. In particular, computer modeling was used to simulate an increased concentration of protons, thereby mimicking the acidic conditions found in inflamed tissues.

“By computer simulations at low pH, a hallmark of injured tissue, we designed an agonist that, because of its low acid dissociation constant, selectively activates peripheral μ-opioid receptors at the source of pain generation,” wrote the article’s authors. “Unlike the conventional opioid fentanyl, this agonist showed pH-sensitive binding, heterotrimeric guanine nucleotide–binding protein (G protein) subunit dissociation by fluorescence resonance energy transfer, and adenosine 3′,5′-monophosphate inhibition in vitro.”

The authors observed that their novel opioid produced injury-restricted analgesia in rats with different types of inflammatory pain without exhibiting respiratory depression, sedation, constipation, or addiction potential. These results, the authors suggested, mean that treating postoperative and chronic inflammatory pain should now be possible without causing side effects. Doing so would substantially improve patient quality of life.

“In contrast to conventional opioids, our NFEPP-prototype appears to only bind to, and activate, opioid receptors in an acidic environment,” explained the study's first authors, Dr. Viola Spahn and Dr. Giovanna Del Vecchio. “This means it produces pain relief only in injured tissues, and without causing respiratory depression, drowsiness, the risk of dependency, or constipation."

"We were able to show that the protonation of drugs is a key requirement for the activation of opioid receptors," the authors concluded. Their findings, which may also apply to other types of pain, may even find application in other areas of receptor research. Thereby, the benefits of improved drug efficacy and tolerability are not limited to painkillers, but may include other drugs as well.

http://www.genengnews.com/gen-news-highlights/opioid-acts-only-on-hurt-tissues-skips-side-effects/81253978

Sunday, July 23, 2017

The Opioid Row Is Directly Relevant To All Neuropathy Sufferers


Today's post from startribune.com (see link below) is of interest to all neuropathy patients, even if you are only taking paracetamol to reduce your symptoms. It addresses the so-called opioid addiction problem but remember, once you begin serious treatment for your neuropathic pain, you're taking drugs meant for other conditions and they all have potential side effects and potential addiction problems. Most people start for instance, with Amitriptyline (which seldom works when neuropathy takes hold but even this is an antidepressant and can have adverse effects on your health. From that point on, the drugs just get stronger, until after you've exhausted them all, you end up on opioid family medications and remember...this is just to control the pain...it does nothing to help the nerve damage itself. So yes, this article applies directly to you and is worth taking sides on. The point of the article is that although politicians claim this is an 'addiction and criminality' problem, it's not, it's a chronic pain problem for which those drugs are ultimately the only solution. Therefore the article quite rightly aims for a course of treatment that is multi-disciplinary and includes drugs but also many other ways to tackle chronic pain. If you scan down the title list to the right of this blog, you will find many articles relating to non-drug treatments to help you live with chronic pain - they need to be included in any doctor's approach to chronic pain. so that you don't just walk away with a prescription for hard drugs in your hand but have a list of other tools which will reduce the need for those drugs and help cope with chronic pain as well. However, don't be fooled...the drugs are necessary; the pain is real and you're not a junkie for needing them. It's just that you can help yourself in other ways too. Worth a read.


Drop old doctor-centered model for a proactive, self-care approach. 
By James Fricton, Alfred Clavel and Mark Weisberg
April 15, 2016

 
Health care and addiction: Instead of opioids, prevent chronic pain


The effort announced by the Obama administration to address the growing opioid abuse problem misses the mark on why people become addicted to opioids. The real reason for the increase in opioid use is not about addiction, but rather about chronic pain.

Thus, the March 27 front-page article (“Taming the pain without the pills”) on an innovative approach to help opioid-addicted patients with chronic pain is important and timely.

While major efforts are underway to prevent most other major health conditions, preventing chronic pain remains an enigma, overlooked by the public, neglected by the health care system and generally ignored by the scientific community. Chronic pain is the “elephant in the room” of health care, and we need to prevent it.

The Institute of Medicine (2011) and the National Pain Strategy (2016) state that chronic pain conditions are the No. 1 reason for the use of opioids, the No. 1 reason for seeking care, the No. 1 cause of disability and the No. 1 driver of health care costs — costing more than cancer, heart disease and diabetes. It costs the United States alone over $700 billion in health care and lost work. This is equivalent to 25 percent of total health care costs and nearly 5 percent of the U.S. total gross national product.

The personal impact in terms of suffering, loss of function, disability, depression, addiction, overdoses and more is incalculable.

The Obama administration strategy suggests that we need to wean thousands of people off these powerfully addictive substances or avoid distributing them in the first place. However, this assumes that people are taking them for nonmedical reasons. In the vast majority of cases, people have been prescribed opioid medications to manage chronic pain.

If we want to reduce opioid addiction and overdoses, we must focus more effort on preventing chronic pain without opioids. Pain conditions in the back, neck, head, face and other areas are caused by physical disorders of the muscles, joints, nerves and other tissues that may begin with an injury or strain and that then may persist due to the lifestyle risk factors that increase sensitization of the nervous system. Repetitive strain, poor sleep, stress, maladaptive postures, emotional problems and other factors can delay recovery. The majority of those with pain over one month in duration still have pain years later despite the use of opioids, pharmaceuticals, implanted devices, surgeries and other innovative treatments.

It’s time we shift the focus to preventing chronic pain. We spend billions on advances in pharmaceuticals, devices, surgeries and other innovative treatments for chronic pain, yet we fail to deliver long-term relief, primarily due to the lack of educating patients in self-management strategies to reduce these risk factors and enhance protective factors.

The Institute of Medicine states that the primary role of the health professional in caring for chronic pain requires guiding, coaching and assisting patients with day-to-day self-management, in addition to evidence-based medical treatments. However, most health professionals lack the time to perform this role and find little support and reimbursement for doing so. They rely on the patient to do so, but this often does not get done. The opioid epidemic is just one of many consequences.

We need to change our health care system. Solving the chronic pain problem requires changing our health care model from a passive model of doctor-centered care to a patient-centered transformative care model. Transformative care brings together evidence-based treatments with self-management training to reduce risk factors and enhance protective factors in each aspect of a person’s life. It helps people shift the balance from illness to health. Embracing patient-centered health care paradigms such as self-responsibility, education, personal motivation, social support, strong provider-patient relationships and long-term change are the key.

We also need to train health professionals and patients on how to prevent chronic pain and opioid addiction. One innovative example of this is the massive open online course (MOOC) titled “Preventing Chronic Pain: A Human Systems Approach” (www.coursera.org/course/chronicpain). This course provides free online education to help those who want to prevent chronic pain and opioid addiction. Course evaluations found 93 percent believed that the course made a difference in their lives and that 85 percent of health providers believe that it made a difference in their patient care. As one participant stated, “Absolutely fascinating and enlightening. This information should be part of every health care educational program!”

Patients and health care professionals can shift the balance from a passive, dependent role to one of being empowered, engaged and well-trained to not only prevent their chronic pain, addiction and disability but also to enhance health and well-being. Ultimately, this will best prevent the opioid problem, improve the quality of health care and significantly reduce health care costs. The “elephant in the room” will finally get addressed. Why not support this?

Dr. James Fricton is a professor and specialist with the HealthPartners Institute for Education and Research, the Minnesota Head and Neck Pain Clinic and the University of Minnesota. Dr. Alfred Clavel is a neurologist with the Minnesota Head and Neck Pain Clinic and department chair in pain management at HealthPartners. Dr. Mark Weisberg is a clinical psychologist with the Minnesota Head and Neck Pain Clinic and the University of Minnesota.

http://www.startribune.com/health-care-and-addiction-x2009-x2009-instead-of-opioids-prevent-chronic-pain/375905321/

Sunday, July 16, 2017

Inconsistent Opioid Prescription Confusing For Patients


Today's post from the ever consistent pain-topics.org (see link below) looks once again at the problems surrounding opioids, especially in North America. More and more people who are genuinely in need of opioids as the only way of controlling their pain, are finding their supplies cut off because of severe legislation meant to tackle drug abuse and crime. Somehow the legislators haven't found a way to separate the genuine need from the addiction which feeds criminality, so are using a 'cover all' approach which means thousands of people are being unfairly treated. It's a growing problem as more and more doctors and pharmacies are reluctant to issue opioid prescriptions for fear of running foul of the law.

Influences on Opioid Rx for Chronic Pain Studied

Posted by SB. Leavitt, MA, PhD Friday, August 9, 2013

Opioids are still among the most commonly prescribed analgesics for treating moderate-to-severe pain. Overall, their use has been increasing even though prescribers are becoming concerned about adverse effects, misuse and abuse, morbidity and mortality, and scrutiny by federal and state regulatory agencies. Two recently published surveys of healthcare providers show that some have stopped prescribing opioids entirely for chronic noncancer pain while others, having more experience with opioids and positive attitudes, continue to prescribe these essential drugs without reluctance.

Opioid Prescribing Changes in Washington State Surveyed

In the first study, researchers in Washington State conducted a survey of primary care physicians and advanced registered nurse practitioners (ARNPs) in the state to understand changes in practice patterns regarding the prescription of opioids for treating chronic noncancer pain (CNCP) [Franklin et al. 2013]. Data were gathered via a web-based anonymous survey conducted during March-August 2011. Participants included a convenience sample of healthcare providers in Washington representing diverse geographic regions and healthcare organizations.

Writing in the July/August 2013 edition of the Journal of the American Board of Family Medicine the researchers report that 623 of 856 provider respondents (73%) claimed to treat patients with CNCP, and these practitioners served as the analysis sample. Most of these providers (72%) reported concerns about opioid overdose, addiction, dependence, or diversion, while only 25% indicated concern about regulatory scrutiny.

Only a small proportion of providers overall (3.3%) said that they had stopped prescribing opioids for CNCP, but twice as many ARNPs (5.8%) as physicians —MDs or osteopaths — (2.1%) reported opioid discontinuation. At the same time, a greater proportion of physicians (71%) than ARNPs (40%) reported familiarity with the Washington State opioid dosing guidelines then in existence.

Of interest, physicians in a large health plan serving 400,000 members in Washington (Group Health), which has substantial infrastructure support, reported less concern about problems with opioids compared with providers in other settings. For example, no providers with Group Health had stopped prescribing opioids; whereas, of providers in Spokane (the largest city in Eastern Washington), 45% reported very low capacity to access pain specialty consultation or other support and consequently were less frequent prescribers of opioids at any dose.

The vast majority of providers reported a need for more efficient, innovative means of support and education related to treating patients with CNCP. Overall, prescribers in Washington reported ongoing concerns regarding opioid use for CNCP, but those affiliated with a large healthcare organization and having access to pain consultation were less likely to report being concerned about opioid-related problems or to have discontinued prescribing opioids.

Opioid Rx Rates Influenced by Prescribers’ Attitudes and Experience

The second study was industry-sponsored (Janssen Scientific Affairs) and published in the June 2013 edition of the Journal of Pain. Researchers found that practitioners’ attitudes about pain drugs closely affect how often they prescribe opioids for CNCP (chronic noncancer pain) [Wilson et al. 2013]. As might be expected, negative physician attitudes about opioid medications appear to be associated with lower rates of prescribing and more favorable attitudes are linked with higher prescribing levels.

This study, conducted by University of Washington researchers and collaborators, used a 38-item questionnaire to assess present-day attitudes reflecting impediments and concerns regarding opioid prescribing, perceived efficacy of opioids, medical education, and benefits of tamper resistant formulations (TRFs). Of 1,535 physicians assessed in the final survey more than 70% reported using opioids in fewer than 30% of their patients with CNCP.

Of particular interest, those physicians who treated higher volumes of patients experiencing CNCP were more likely to prescribe opioids and said that they were less concerned with impediments surrounding opioids, were not worried about or avoidant of prescribing Schedule II vs. Schedule III drugs, believed in the benefits of TRFs, and thought that they were adequately trained to treat chronic pain.

According to the researchers, these results are consistent with other studies showing that physician uneasiness with prescribing long-term opioids for chronic pain is linked with inexperience in using the medications. There were no differences evident in overall physician attitudes about opioids in various areas of the country; however, the researchers noted that orthopedists expressed the most negative views of opioids, showed the lowest level of confidence in opioid efficacy, and had the highest average levels of concern about opioid addiction, tolerance, and dependence.

COMMENTARY: The survey by Franklin and colleagues [2013] may be conveying false perceptions that are contrary to current realities in Washington State. For one thing, the survey depicts a point in time that may no longer be relevant; that is, data collection was concluded in August 2011, but the study was not even submitted for publication until 14 months later in October 2012 and was just recently published in summer 2013.

Meanwhile, aggressive new laws (as opposed to mere guideline recommendations) for the management of CNCP — intended to curb opioid-related problems in Washington State — had gone into effect in January 2012 [see discussion in UPDATE here]. In advance of enactment of the new rules, some reports noted that as many as 70% of community health clinics in the state had stopped treating patients with chronic pain, and most of those that still did treat such patients would not provide opioid analgesia. Therefore, the out-of-date survey by Franklin et al. may grossly understate the extent to which prescribing practices negatively changed in the state.

Furthermore, the survey by Franklin et al. used a convenience sample, with a low response rate, that was slanted toward physicians in the large and highly supportive Group Health system. These respondents were less intimidated by opioid-dosing guidelines than other prescribers in the state — eg, none in Group Health had completely discontinued opioid prescribing — but this may or may not hold true today, more than 2 years after the survey. Meanwhile, all indications are that problems have grown worse rather than better for patients who might benefit from opioid therapy for chronic pain in Washington State; and, there have been other unintended consequences.

For example, according to newly reported research, heroin use is on the rise in Washington State and the upsurge can be traced to the new laws that made it more difficult to obtain prescriptions for opioid analgesics [see June 12, 2013 U.S. News & World Report article here]. Implementation of the new opioid-Rx laws decreased the numbers of people abusing opioid analgesics, but also increased the demand for heroin in the state.

As noted by study author Caleb Banta-Green of the University of Washington, “We were either progressive or regressive with that aggressive effort to reign in opiate prescribing before a lot of the country.” He conceded, “It shows if you enact these laws, you get some of the intended effects — high school sophomores have significantly decreased the rate at which they’re abusing prescription opiates — but people are also diverted to heroin.” This increase in heroin use is not new, and has been occurring nationwide as regulators and legislators have tried unsuccessfully to grapple with opioid-related problems [see most recent UPDATE on this topic here].

The second study noted above, by Wilson et al. 2013, appears to confirm general assumptions that prescriber attitudes toward opioid prescribing are favorably influenced by their education and experiences in using the drugs and by treating more patients with CNCP. It seems to be a case of familiarity with opioids and their effectiveness builds comfort that overcomes other concerns.

Among the various speciality groups surveyed, orthopedists were most troubled by impediments/concerns relating to long-term opioid use and had the least confidence in opioid efficacy, whereas pain medicine specialists and physical medicine and rehabilitation specialists were the most confident in opioid use and effectiveness. However, it must be considered that orthopedists most often treat patients with acute pain conditions and have less familiarity with CNCP.

The survey revealed additional factors that may influence attitudes and prescribing practices; although, the significance and universal applicability of these should be circumspectly considered. For example, male physicians on average believed more strongly in the efficacy of opioids for CNCP than females; physicians less than 45 years of age were slightly less confident in prescribing opioids compared with those between 45 and 60 years; and physicians with less than 10% of their patients having chronic pain believed significantly less in opioid efficacy compared with those having greater percentages of patients with CNCP.

Taken together, the two studies appear to emphasize practitioners’ needs for evidence-based guidance, tools and resources, as well as ongoing education regarding benefits and risks of opioid analgesics for CNCP. As might be expected with any medical therapy, practitioner confidence and expertise increase as opioid prescribing experience accumulates. This further suggests that generalizations about successes or failures of opioids for treating CNCP conditions should take into account differential qualifications, attitudes, and beliefs of the prescribing healthcare providers.

REFERENCES: > Franklin GM, Fulton-Kehoe D, Turner JA, et al. Changes in Opioid Prescribing for Chronic Pain in Washington State. J Am Board Fam Med. 2013;26:394–400 [access here].
> Wilson HD, Dansie EJ, Kim MS, et al. Clinicians' Attitudes and Beliefs About Opioids Survey (CAOS): Instrument Development and Results of a National Physician Survey. J Pain. 2013(Jun);14(6):613-627 [abstract].

http://updates.pain-topics.org/2013/08/influences-on-opioid-rx-for-chronic.html

Wednesday, July 12, 2017

Opioid Dependency Whats It Got to Do With HIV


Today's post from thebody.com (see link below) is the second part of an examination of opioid dependency (see yesterday's post). This time it concentrates more on why this may be a problem for people living with HIV and what they should look out for and be aware of when taking these drugs. Being HIV+ unfortunately doesn't rule out getting other diseases as well, as  people with neuropathy and HIV are painfully aware of. That's why it's so important to arm yourself with as many facts about your treatment as possible.

Opioid Dependency: What's It Got to Do With HIV?

By Dave R. February 1, 2013

Internet links shown in these posts are designed to provide more detailed information if required.

This article is Part Two of a two-part piece. Read Part One, "The Opioid Solution and HIV: From the Frying Pan Into the Fire."

"Only the patient knows how intense and frequent a pain is - a pain is what the patient says it is." -- Palliative caregiver

So what is the 'real and present danger' to us as people living with HIV, its co-morbidities and any resulting extra health problems? If your pain does not respond well enough to analgesics and other drugs (anti-depressants, anti-convulsants and other drugs meant to interact with nerve signals to the brain), you may be advised to move onto opioids of one sort or another. This shouldn't alarm you too much, despite the content of Part One of this article.

Opioids work really well, if they are kept under control and you are consistently monitored by your doctor or specialist. He or she should make every effort to ensure that you don't become addicted whilst still getting the most relief out of the pain killing effects. The problems often begin if the doctor writes you a prescription and then leaves you to get on with it. You should always discuss any potential side effects and problems before beginning with opioids. You should get his or her reassurance that you will be carefully monitored and that the right level of opioid medication will be found with as little risk of addiction as possible. Anything less is really unacceptable but the reality is often harder than this advice suggests. If you're given a ten minute appointment, it may be difficult to discuss things in any detail because the doctors are under so much time pressure. However, in this case, you can be sure that a little time spent establishing ground rules now will save much more of the doctor's time later if it goes wrong. If you want to get off the drugs at a later date, make sure that the close monitoring continues: weaning yourself off opiates is no casual matter and isn't easy; you're going to need support. In your own interests, make sure you get it.

The American Institute of Addiction Medicine points out that the World Health Organisation recognises opioid addiction as a brain disease. Addiction also involves a physical, psychological and behavioural need for an opioid and can dominate a person's life. They also say that opioids prescribed as painkillers are similar to heroin and can be equally addictive.

Addicts will go to any lengths to satisfy their need, including shopping around the various doctor's surgeries and clinics, stealing from friends, family and work and using the internet to order them from whatever suspect source. The withdrawal symptoms of coming off opioids should never be underestimated. It's always possible but it's going to be hard -- you'll probably need help, guidance and understanding. Never try to go cold turkey with opioids; you don't need to; just get the right advice. Some people, however, will continue their addiction rather than face the social stigma of admitting their problem and seeking help.

The medical authorities and pharmaceutical companies are finally reacting to the problem and working on ways to reduce the potential for pill abuse by developing safer alternatives with longer delayed release effects, to try to cut out the possibilities for instant highs. They are also busy studying the best ways of directing and re-directing pain signals to the brain by creating more refined opiate derivatives but this will take time, especially as each new product has to go through hoops before it is officially approved.

In the meantime, millions of people suffer from substance use and abuse and many more are affected by someone else's problems. The best we can all individually do is keep our eyes open in our own circles. If you know someone who has been prescribed opioids for chronic pain, tactfully try to let them know that you will be there for them during any difficulties and watch out for signs of a personal struggle with the drugs. Of course this is true for all substance abuse; from over-eating, to alcohol and smoking, to heavier medication abuse. If for whatever reason you personally take opioids for recreational purposes, I can't judge but please make yourself aware of the facts and the dangers and if you feel that control is slipping away and the drugs are taking over, at least tell someone you trust. You really don't want to become another drug abuse statistic, especially if you are also living with HIV; life is surely difficult enough!

I don't want to come over as alarmist; the statistics surely speak for themselves and opioids are powerful analgesics that when properly and sensibly prescribed and administered, can bring much needed relief from physical pain and emotional suffering. However, they aren't aspirins and need to be treated with the greatest of respect. If you take them because your pain is unbearable, you have to see them as a positive treatment; you may not have any choice, but knowledge is power and being aware of what they can do if not wisely used is half the battle against potential problems. If you're honest with yourself, you may become more aware by looking at other things in your life. Do you find it difficult to resist smoking, drinking, eating, for instance? I know I have a history of being open to temptation and may have a 'suggestible' personality. Perversely, that knowledge helped me stop smoking, drinking and certainly helped when coming off Oxycontin. Knowing that you are susceptible to mild addictive behaviour may keep that thought in the back of your mind when dealing with opioids. Never be afraid to pester your doctors for help - they can't read your mind.

Finally, the following by Jane Ballantyne and Steven LaForge from the official journal of the American Pain Society sums up how difficult the whole subject is.

"When patients are maintained on opioids for the treatment of pain, there is currently no satisfactory means of distinguishing true addiction from problematic behaviors caused by a variety of factors other than addiction. Unfortunately, advances in understanding the neurobiological foundation of addiction have not been matched by any improvement in physicians' ability to recognize and diagnose the condition. There is no single diagnostic marker of addiction, no definitive change on brain imaging and as yet no genetic markers to provide a reliable prognosis of risk. When it comes to iatrogenic opioid addiction, the clinician is faced with even greater difficulty: the behaviors encountered do not resemble those outlined in the criteria for addiction to illicit drugs...

... One of the great difficulties of quantifying, recognizing, and treating iatrogenic opioid addiction is the subjective nature of the judgment on whether behaviors have crossed an ill-defined boundary between problematic opioid use and addiction. This judgment then becomes dependent on the reporting person's experience, prejudices, and knowledge."

Ballantyne JC, LaForge KS. Opioid dependence and addiction during opioid treatment of chronic pain.Pain. 2007;129(3):235-255

Opioid dependency is clearly a huge problem, partly because of the dichotomy of its causes. How can you balance the medical need for perfectly legal and effective drugs, with the potential for side effects and addiction? Addicts may become addicted because the opioids have overcome the original medical need and prescription parameters, or because they're seeking a buzz or a high? The end result for both can be addiction, even if the original motives were poles apart.

The lines are blurred and nothing is just black and white but there is no doubt that it's another underestimated problem of the modern age, which is having wide ranging effects of certain groups in society. The authorities are, as is often the case, reacting instinctively by using sledge hammers to crack nuts by locally banning this and that and criminalising doctors and chemists, who have to turn legitimate patients away.

It is complex and we have to hope that the pharmaceutical companies will ignore their cash cows and quickly come up with safer but equally effective alternatives. Let us hope that people living with HIV are amongst the most knowledgeable and level headed in society and that the problem within our community will be constrained, even if it can't be removed.
Further Information

Opioids911-Safety

Opioid Risk Management

The Urgency of Pain Control in Adults With HIV/AIDS

This and other posts are based on my opinions and impressions of living with both neuropathy and HIV. Although I do my best to ensure that facts are accurate and evidence-based, that is no substitute for discussing your own treatment with your HIV specialist or neurologist. All comments are welcome.

Read Part One of this piece, "The Opioid Solution and HIV: From the Frying Pan Into the Fire."

http://www.thebody.com/content/70427/opioid-dependency-whats-it-got-to-do-with-hiv.html

Sunday, July 2, 2017

The Opioid Solution and HIV


Today's  post from thebody.com (see link below) talks about a hot topic in the US right now and that is opioid use and abuse. If you are a chronic pain sufferer and let's face it, many people living with neuropathy are; then you may end up being prescribed opioids. These can turn out to be the only effective method of controlling the symptoms although they are never a cure! Dependency can be an unfortunate result (as well as other side effects) but it really is up to your doctors or specialists to monitor you carefully, so that the risk of addiction is minimized. Unfortunately, due to opioid misuse and the crack down upon it, people are being tempted towards heroine and other substitutes and the black market is growing again. People with genuine needs for opioid treatment are being denied their drugs because pharmacists and doctors are afraid of falling foul of new laws. Thankfully, the pharmaceutical companies are coming up with abuse-resistant, slow-release opioids but these are by no means available everywhere. The article looks at the problem as a whole.


The Opioid Solution and HIV: From the Frying Pan Into the Fire

By Dave R. February 1, 2013

Internet links shown in these posts are designed to provide more detailed information if required.

This article is Part One of a two-part piece. Read Part Two tomorrow, "Opioid Dependency: What's It Got to Do With HIV?."

"Pain is experienced by people and families not by nerve endings." -- Dame Cicely Saunders

A nightmare for some and a godsend for others, some people become addicted to opioids because opioids have become their recreational drug of choice, while others become addicted because their pain symptoms are so severe that they have no choice. Either way, a problem has arisen which threatens social stability in whole communities, especially in North America, and makes authorities unsure which way to turn.

You may see this as a "far from my bed" phenomenon but as I will explain later, many people living with HIV find themselves involved with opioids before they know it and have to live with the consequences of this sort of treatment simply because there is no better way of treating their pain.

First some statistics to highlight the scale of the problem:

According to the US Institute of Addiction Medicine, in 2007, 23 million people over the age of 12 needed treatment for substance abuse in the USA.
Between 1992 and 2003, abuse of prescription drugs increased by 140%.
Given that Americans represent 5% of the world's population, 80% of the world's supply of opioids and 99% of the global availability of hydrocodone is used within the US borders.
Because opioids are legally available as prescription drugs, this availability has been matched by a 63% increase in opioid-related deaths between 1999 and 2004.
Many studies have shown that abuse or misuse of these drugs averages out at between 20% and 58% of people who have been prescribed opioids for chronic pain.
In 2005 it was established that almost 2 million Americans were opioid dependent but more alarmingly ...
Approximately 4.7 million teenagers and adults used opioids for non-medical purposes and ...
Over 32 million Americans reported having used them for non-medical purposes at least once in their lives.

Shocked yet? Actually these statistics were assembled before the current explosion in opioid addiction and abuse that has recently begun to hit the headlines across the western world. The figures, five years later in 2012, will be far higher; and the number of deaths and serious health problems resulting from both opioid prescription and the black market will now be alarmingly high. It's a problem that is almost unrecognised in its expanse, and a social time bomb that we still seem unwilling to acknowledge.

Still, why should this be relevant to people living with HIV? The answer is that many people with HIV are also chronic pain patients, something that is often overlooked when reading about the negative aspects of being positive.

According to The Well Project, many people with the virus have to manage chronic pain symptoms for the following reasons:

Peripheral neuropathy (between 25% and 40% of people with HIV) -- nerve damage with over 100 causes, amongst which are the virus itself, diabetes, cancer treatment, toxic medications and even high alcohol consumption.

Abdominal pain (26% ...) -- as a side effect of some HIV drugs; parasitical infection or bacteria; problems and irritability in the intestines, including irritable bowel syndrome; inflammation of the pancreas caused by some HIV meds; too much fat in the blood; or drinking; bladder or urinary tract infections and in women, uterus, cervix and ovary conditions.

Headaches and migraines (17% ...) -- from mild to severe brought about by a variety of causes including certain HIV drugs

Joint, muscle and bone pain (5% ...) -- can also be from mild to severe and be HIV-related to forms of arthritis, rheumatism, bone disease and bone density problems. It can also occur when using drugs for high cholesterol and especially hepatitis.

Herpes pain (5% ...) -- many people may see herpes as par for the course when you're sexually active but a cold sore, or sore on your genitals, represents its mildest form. If you've ever had shingles, you'll know that the pain can be excruciating and as the herpes virus can frequently re-occur, it's something that can plague your life if you have HIV.

Skin problems and rashes -- side effects of certain HIV medications or other drugs.
Chest pain caused by lung infections such as TB, bacterial pneumonia, or PCP pneumonia.

Mouth pain caused by ulcers or fungal infections.

Pain due to cancer in all its forms.

According to pain.com, in 2005, 8% of HIV individuals were on long-term opioids (especially Oxycodone and Tramadol) for severe pain, which was more than double the non-HIV population. However, the good news is that the explosion in opioid use since then has not been paralleled in the HIV population. This is possibly because opioids are prescribed for valid reasons to HIV patients and there is less incidence ofrecreational opioid use which has worsened the problem in the general population.

Before everybody writes in to say that they're fine and have never had a problem with the virus or the medication, please be reassured that you are some of the lucky ones. Of course only a certain percentage of people living with HIV will suffer chronic pain in one form or another but a significant proportion of those will eventually have no option but to start taking opioids as the only painkillers that will help. It's not a choice; some pain is so severe that it just doesn't react to over-the-counter medications, or medications meant for other diseases. Opioids, if used properly, are a very effective solution. The problem is that they are not always used properly, as the statistics above clearly show.

Recreational use of opioids could also be said to be the result of psychological 'pain': fulfilling a need to escape from the harsh edges in life (it could also be simply the well-known search for a kick that has got out of hand). However, recreational drug use and the reasons for its popularity are really subjects for other articles. What we need to know to arm both ourselves and people we know with knowledge, is that it gets out of hand when people don't realise how quickly and easily they can become seriously addicted.

So, with the facts out of the way, it's perhaps useful to illustrate the problem by giving some examples of what opioid abuse and the authorities attempts to crack down on it have been doing to people.

Information From the USA

In July this year, the FDA instructed companies to cease the manufacture and distribution of certain drugs containing Oxycodone (Oxycontin). These are specifically single ingredient and immediate release drugs, including capsules, tablets and oral solutions. The principal reason for this is the ease with which they can be abused. Crushing a pill and smoking or snorting it will provide an instant high and therein lies the danger for speedy addiction problems.

The idea is that these immediate release drugs will be taken off the market thus nipping the problem in the bud. However, it is a slightly clumsy measure for two reasons: determined addicts will head underground or on the internet for their supplies from other countries and people in genuine medical need will be cut off from their source. The pharmaceutical companies are busy developing new versions of opioids which only have a delayed release effect but the ban came before these were widely available. The word 'distribution' in the ban also meant that doctors and pharmacies could no longer supply their patients with their regular pain relief, thus creating a vacuum which has only increased suffering for many people.

Apart from the FDA trying to cover their backs in relation to the prescription abuse epidemic, the U.S. Senate ordered an investigation into the pharmaceutical industry and in particular Purdue Pharma, the manufacturers of Oxycontin. Not only that but the investigation extends to their funded pain organisations and physicians who are suspected of profiting from the prescription drug problem.

An article in the Salem News, discusses the problem:

"Senate Finance Committee Chairman Max Baucus of Montana and Senator Chuck Grassley of Iowa sent letters to Purdue Pharma, Endo Pharmaceuticals, Johnson & Johnson and nine pain organizations, saying "there is growing evidence pharmaceutical companies that manufacture and market opioids may be responsible, at least in part, for this epidemic by promoting misleading information about the drugs' safety and effectiveness."

And from the same article:

"'Improper relationships between pharmaceutical companies and the organizations that promote their drugs can put lives at risk. These painkillers have an important role in health care when prescribed and used properly, but pushing misinformation on consumers to boost profits is not only wrong, it's dangerous,' Sen. Baucus said in a statement."

The official line then seems to be based on sound concerns and we must applaud people who keep a close eye on the workings of the multi-billion dollar pharmaceutical industry but in this case, it doesn't solve the immediate problem. There are hundreds of thousands of people, including many living with HIV, who need their pain relief to get through the day and for genuine reasons. Then there are the many addicts who also can't be cut off without help and some sort of slow weaning-off program. To many people's surprise, this very dilemma has led to a resurgence in heroin use -- these people needsomething, they can't just be abandoned to get on with it themselves.

Kentucky officials recently began a system of electronically tracing pills and found that there was a pipeline of opioids coming in from Florida. Cracking down on this sort of supply route means that opioid analgesics become much harder to find, even on the illegal circuit; but this also leaves the door open for substitutes such as heroin. The heroin has been traced back to Mexico and Central America and as always, supply and demand runs the show. A single Oxycodone pill can cost between $80 and $100 and a single hit of heroin, with 24 hours working value, can cost as little as $15 to $20! You do the math.

They should really have waited until there were sufficient delayed-release opioid pain killers on the market before removing them from official outlets and cracking down on drugs pipelines; but they didn't, and people addicted for whatever reason have needed to deal with their pain. Heroin, however attractive, is a frightening option and hopefully legitimate patients will never go down that road.

It's important to remember that Oxycontin is by no means the only opioid that has these troubling side effects. Morphine family members -- including amongst others, Tramadol, Dilaudid and Percodan -- all have their own stories of widespread addiction after delivering relief from chronic pain.

A paper produced by the Ontario Addiction Treatment Centres makes for very interesting and alarming reading, the chief points of which are as follows:


The main causes of drug-attributable deaths are suicide, overdose and AIDS contracted from sharing needles - all of which are strongly associated with injection drug use.
Each year, about 1% of opioid users will die from an overdose.
In 1995, opiate poisoning was the cause of about 160 out of 804 drug-related deaths in Canada, and opioids accounted for 11% of the 6,947 hospitalizations attributed to illicit drug use. (This does not include the hospitalizations for inappropriate use of prescription opioids.)
People who are opioid dependent are also extremely vulnerable to life-threatening blood-borne diseases, such as HIV and hepatitis C. Between 1985 and 1999, the proportion of people in Ontario diagnosed with HIV through injection drug use rose from 0.45% to almost 15%. In 1999 alone, injection drug users accounted for 24% of new HIV infections in Northern Ontario and 15% of new HIV infections in Ottawa. As of 2000, 63% of newly diagnosed cases of hepatitis C are related to injection drug use.
In 1999/2000, drug possession or drug trafficking accounted for 7% of new admissions to correctional institutions (2,110 people), 5% of new admissions to probation (1,809 people) and 16% of new admissions to conditional sentences (694 people). These figures do not include the number of people convicted of theft or other crimes to support a drug habit.
The Ministry of Community and Social Services estimates that about 3% of users of the social assistance or welfare system have a history of drug dependency, which affects both their employability and their ability to maintain employment.

It's again important to remember that this paper was drafted some years ago and since then the opioid problem is said to have 'exploded', which if true, is a frightening thought. Whether the problem has really become so much greater since 2000 is open to discussion. The truth may be closer to the fact that the media in western countries has finally cottoned on to the extent of the problem and has devoted column inches to lurid and sensationalist headlines which make it look as though the opioid addiction problem is explosive and threatening to the social fabric.

This and other posts are based on my opinions and impressions of living with both neuropathy and HIV. Although I do my best to ensure that facts are accurate and evidence-based, that is no substitute for discussing your own treatment with your HIV specialist or neurologist. All comments are welcome.

http://www.thebody.com/content/70426/the-opioid-solution-and-hiv-from-the-frying-pan-in.html


Sunday, June 18, 2017

Tapentadol An Opioid Option For Severe Neuropathy


Today's article from medscape .com (see link below) talks about a drug that has been on the market for a short time  but has had displayed good results for patients with severe and painful neuropathy. The problem is that it's an opioid (although one of the better-tolerated opioids) and there are two objections that stand in the way of it being more widely prescribed. It's apparently expensive and insurance companies are reluctant to pay for it and possibly because of that, the moral argument against opioids in general (addiction dangers, public image) is strengthened. Tapendatol (Nucynta) however, has had such good results with less side effects, that many specialists are wondering why it isn't more widely prescribed. You are unlikely to be prescribed opioids unless your pain is severe and chronic and you've already been through the gamut of other options and even then many doctors are also biased against opioids. New evidence has shown however, that if used properly and under supervision, opioids can be extremely useful in reducing nerve pain and improving the quality of life of patients and Tapentadol seems to be step forward in refining opioids for safer use. Maybe worth discussing with your doctor, if the pain is affecting your life badly.


Tapentadol is 'Third-Tier' Drug for Diabetic Neuropathic Pain
Lara C. Pullen, PhD June 04, 2014

The opioid analgesic tapentadol (Nucynta, Janssen Pharmaceuticals) is approved for use in patients with painful diabetic peripheral neuropathy in the United States, but it is expensive, and most insurance companies require physicians to first attempt multiple other drugs before prescribing it, says the lead author of a new paper describing the efficacy and tolerability of this agent.

The agent is also a scheduled narcotic, which further deters doctors; thus, tapentadol is currently a "third-tier" drug for the treatment of diabetic peripheral neuropathy, Aaron I. Vinik, MD, PhD, from East Virginia Medical School in Norfolk, told Medscape Medical News.

Dr. Vinik and colleagues' findings were published online May 21 in Diabetes Care. While the results show tapentadol is an effective treatment for diabetic peripheral neuropathy, "it is not being prescribed as much as I thought it would be," he said.

John D. England, MD, from the department of neurology at Louisiana State University Health Sciences Center School of Medicine in New Orleans, who was not involved with this research, agrees that doctors are uncomfortable prescribing this agent.

"[Tapentadol] is a [Drug Enforcement Administration] schedule II narcotic and has significant potential for abuse and addiction. It is only indicated for moderate to severe pain. For the treatment of neuropathic pain, there are many other drugs that are safer and have fewer adverse effects. This drug, like all opioids, would be a last-tier option for neuropathic pain," he explained in an email.

Dr. Vinik says he also has another reason to hesitate when considering tapentadol for this indication, "I prescribe it in very specific circumstances. I am keen on managing diabetic peripheral neuropathy based on comorbidity," he elaborated.

Tapentadol ER Effective and Well Tolerated


An extended-release (ER) formulation of tapentadol was approved for use in painful diabetic peripheral neuropathy by the Food and Drug Administration in August 2012, and the United States is currently the only country in which this agent is approved for this indication.

In the newly published study by Dr. Vinik and colleagues, adults with moderate to severe diabetic peripheral neuropathy pain were titrated to tapentadol ER 100 to 250 mg twice daily during a 3-week open-label period. Patients with 1-point or more reduction in pain intensity (11-point numerical rating scale) at the end of titration were then randomized to receive placebo or tapentadol ER, at the optimal dose determined from titration, for a 12-week, double-blind, fixed-dose maintenance phase.

The primary end point was mean change in average pain intensity from the start to week 12 of the double-blind maintenance phase.

A total of 358 patients completed the titration period; 318 patients (placebo, n=152; tapentadol ER, n=166) were randomized and received 1 or more doses of double-blind study medication. Mean pain intensity was 7.33 at the start and 4.16 at week 3 of the open-label titration period (mean change, –3.22).

The mean change in pain intensity (a positive value indicates worsening of pain) from start of double-blind treatment to week 12 was 1.30 for placebo vs 0.28 for tapentadol ER (P lt; .001 in favor of tapentadol).

Dr. Vinik said while there was quite a high rate (35%) of gastrointestinal disturbances, such as nausea and vomiting, observed with tapentadol ER, as well as a high rate of dizziness (12%) and headache (4%), the side effects did not stop patients from taking the medication.

"Tapentadol ER (100–250 mg [twice daily]) was effective and well tolerated for the management of moderate to severe chronic pain associated with diabetic peripheral neuropathy," he and his colleagues conclude.

Treating Pain Based on Comorbidity

However, in practice, Dr. Vinik noted that many patients with painful diabetic neuropathy also experience sleep disorders, anxiety, and/or depression. So physicians should ideally prescribe drugs that will treat as many of these comorbidities as possible, looking for the best fit with the total clinical picture of a patient.

If a pharmaceutical treatment can ameliorate sleep disturbance, it may also have a significant effect on pain, he noted. Unfortunately, in the case of tapentadol and many other drugs prescribed for diabetic neuropathy, their effect on sleep has not been well studied, he observed.

While many physicians and patients believe a number of commonly prescribed medications to have a beneficial effect on sleep, research shows that while an agent may make a patient tired, for example, it doesn't necessarily help the patient to sleep. For instance, a commonly prescribed drug for diabetic neuropathy, duloxetine (Cymbalta, Eli Lilly), actually fragments sleep, he explained.

Dr. Vinik suggests that, when treating a patient with diabetic peripheral neuropathy and sleep disturbance, a gabapentinoid may be the best option.

Anxiety is a common comorbidity with diabetic neuropathy, too, but unfortunately, tapentadol is also not particularly effective for anxiety, he added, noting that tricyclic antidepressants may be the best option for these 2 coexisting conditions.

He warns, however, that tricyclics may have cardiac effects, and thus physicians should take care to evaluate the cardiac status of patients before and after prescribing these older antidepressants.

Depression and Diabetic Neuropathy: A Good Fit for Tapentadol?

The other common comorbidity, occurring in approximately half of all patients with diabetic neuropathy is depression. While tricyclics may be an effective treatment for depression alone, they do not appear to ease the pain of patients with both conditions.

While he cautioned that patients who are bipolar do not respond well to either tapentadol or duloxetine, he said that the unique properties of tapentadol — it is a combination of a µ-opioid-receptor agonist and a norepinephrine-reuptake inhibitor in a single molecule — means it is possible for the physician to prescribe 1 drug instead of 2 for patients with diabetic peripheral neuropathy and classic depression.

For this reason, tapentadol is a good addition to the physician arsenal and can be extremely beneficial for the right patient because it not only relieves pain but also has the potential to elevate mood, he concluded.

Editorial support was funded by Janssen Research and; Development and Grünenthal. Dr. Vinik received funding for this study from Janssen; disclosures for the authors are listed in the article. Dr. English has reported no relevant financial relationships.

Diabetes Care. Published online May 21, 2014. Abstract

http://www.medscape.com/viewarticle/826174

Friday, June 9, 2017

FDAs Opioid Letter To Prescribers


Today's post from the always excellent pain-topics.org (see link below) talks about a letter issued in march 2013 from the American FDA (Food and Drug Administration) to all prescribers of opioids. Thanks to the widespread abuse of opioids, especially in North America, the authorities are clamping down on the ease and regularity with which opioids are prescribed. This has led to many doctors and pharmacists, stopping prescription altogether to avoid legal problems. The consequence of this is that those people for who opioids are a necessary and unavoidable source of pain relief (especially from neuropathy) are finding that the drugs are, in some cases, far harder to come by. This letter from the FDA, far from rubber-stamping political pressure policies, is a sensible and well-thought out advice on how to prescribe opioids as safely as possible. Unfortunately thanks to the extent of the abuse problem, the majority are going to suffer at the expense of a minority. The drug companies can play a part by issuing slow-release versions to avoid the instant 'hits' caused by crushing tablets and then snorting them but these things take time. If you have been directly affected by this issue, please let our readers know of your experiences.

Letter from U.S. FDA to All Opioid Prescribers

Posted by SB. Leavitt, MA, PhD at  Wednesday, March 13, 2013

In early March, 2013, U.S. Food and Drug Administration (FDA) commissioner, Margaret A. Hamburg, MD, sent e-mail to select members of Congress assuring them that the “FDA is extremely concerned about the inappropriate use of opioids, which has reached epidemic proportions in the U.S., becoming a major public health challenge.” She noted that, “While much of the prescription drug abuse problem is attributable to illicit use, which can include sharing medication with family and friends or theft of the drug from home medicine cabinets, legitimate use of medications for pain may also lead to unnecessary adverse events, addiction, and death for some patients.”

Dr. Hamburg asserted the agency’s view that front-line healthcare professionals, especially physicians and other prescribers of opioid analgesics, can and should play an important role in efforts to reduce the adverse trends. In that regard, she issued an open letter to all prescribers, urging them to take advantage of educational programs and other actions designed to “promote responsible opioid prescribing, improve pain management, and minimize prescription drug abuse and diversion.”

Following is the text of the FDA’s letter to opioid prescribers, including active links (opening in separate browser windows) to the websites and documents that are referenced.

^^^^^^^^^^^^^^^^^^^^^^^^^^^^^

Attention Prescribers: FDA seeks your help in curtailing the U.S. opioid epidemic

Summary

In light of the expanding opioid epidemic in the U.S., FDA urges prescribers to take advantage of training on opioid prescribing, available as of March 1, 2013. This voluntary training will be provided at little to no cost through accredited continuing education activities supported by independent education grants.


Taking advantage of training opportunities on opioid therapy, now and in the future, is one of three key roles that FDA sees for prescribers in helping to curtail this pervasive problem. The other two are: knowing the content of the most current drug labels for the opioids they prescribe, and educating patients about the appropriate use of opioids, their potential risks, and proper disposal techniques.


FDA-approved drug labels are frequently updated based on additional science, new benefit-risk information, or public health implications regarding the medication. Labels of extended release and long-acting opioid drugs were changed in July, 2012.

Introduction

Misuse and abuse of prescription opioids has reached epidemic proportions in the U.S. While much of the problem is attributable to illicit use, appropriate use of medications for pain may also lead to unnecessary adverse events, addiction, and death for some patients. No group can be more effective in reducing this trend than our nation’s front-line health care professionals, especially physicians and other prescribers.

FDA sees three key roles for prescribers in curtailing the U.S. opioid epidemic, 1) ensuring that they have adequate training in opioid therapy, 2) knowing the content of the most current opioid drug labels, and 3) educating patients about the appropriate use of opioids, their potential risks, and proper disposal techniques.

Take advantage of important training opportunities

As the opioid epidemic has evolved in recent years, extended-release (ER) and long-acting (LA) (ER/LA) opioids have clearly emerged as products with the highest potential for harm, misuse, and abuse. These products contain large amounts of opioids in a single dosage form, sometimes in sufficient quantity to be lethal, especially in children, and they are a prime target of drug abusers.

In July of 2012, FDA approved a Risk Evaluation and Mitigation Strategy or REMS for these products. A REMS is a risk management plan for a manufacturer to implement that goes beyond the requirements in the drug prescribing information to manage serious risks associated with a drug.

An important element of this REMS is the availability of voluntary ER/LA opioid training programs, at little to no cost, to all U.S. licensed prescribers. The first of these programs is available as of March 1 and more will become available. Although the programs will be funded by opioid product manufacturers, the content will be objective and independent.

The programs will be offered by independent providers of continuing medical education (CME) and based on an FDA blueprint that was developed with input from a wide range of stakeholders. Included will be information on weighing the risks and benefits of opioid therapy, the appropriate choice of therapy for each patient, and managing and monitoring patients and counseling them on the safe use of these drugs.

The program also will include learning to recognize potential for, and evidence of, opioid misuse, abuse, and addiction, as well as general and drug-specific information about ER/LA opioid analgesics. FDA encourages all opioid prescribers to take advantage of this valuable training to help ensure they have adequate and up-to-date training in opioid therapy.

More information can be found at http://www.er-la-opioidrems.com/, which will be updated as additional opportunities become available.

Review and know the most current opioid drug labels

The July 2012 REMS for ER/LA opioids also included significant changes to the FDA-approved drug labels for these products. The revisions focused on making the labeling consistent among ER/LA products, and on increasing the prominence of information available regarding risk and precautions, such as those for abuse and misuse, respiratory depression, and accidental exposure.

The drug label, or package insert, that accompanies all FDA-approved medications is the most complete source of information on the drug. Drug labels provide important safety and efficacy information and clinical data to prescribers on the benefits, risks, and appropriate use for all FDA-approved drugs. The FDA-approved drug label is one of the most useful tools prescribers have for providing safe and effective opioid therapy to their patients.

As with all FDA-approved drugs, each ER/LA opioid product label has information unique to its own chemical compound and formulation. However, ER/LA opioid labels also share many important similarities. Therefore, maintaining a thorough knowledge of the drug labels can help prescribers inform their decision-making to ensure safe, appropriate, and effective use.

Labeling for all FDA-approved opioids can be found on the Drugs@FDA website, as well as at pharmacies and on many manufacturers’ websites. Labeling is also the root source of information prescribers receive from a wide variety of commercial online reference products and other resources educating prescribers about the safe and effective use of FDA-approved drugs.

Keep up with changes to drug labels. It is important to know that drug labels may change as new information on any FDA-approved products becomes available and that these changes occur frequently. We encourage prescribers to regularly review these changes. FDA’s MedWatch site provides easy access to safety labeling changes for FDA-approved drugs. This resource clearly identifies the parts of the label that have changed.

Help educate patients to use opioids safely and effectively

Patient education is vital to safe and effective opioid use. FDA urges all prescribers to ensure patients using opioids are appropriately informed of the risks and benefits of these drugs and fully understand directions for their use. The opioid drug labels also provide prescriber information related to patient education.

FDA-approved Medication Guides are key patient education tools. Pharmacies are required to provide them to every patient who receives an ER/LA opioid. Prescribers can also download all available Medication Guides for use in their offices. Among other valuable information, Medication Guides for ER/LA opioids inform the patient on safe disposal of their unused medication. FDA has also created a patient counseling document that prescribers can use to help educate patients on the safe and effective use of opioids.

Conclusion

FDA remains committed to making sure that patients in need have continued access to appropriate pain medications, while also ensuring that all opioid products are used as safely and effectively as possible under the supervision of prescribers armed with sound information and training. Prescribers are critical to successfully curtailing this national problem.


^^^^^^^^^^^^^^^^^^^^^^^^^^^^^

COMMENTARY: Attached to the letter, as examples, Dr. Hamburg provides specific information available in the FDA-approved labeling for two opioids — OxyContin® (oxycodone controlled release) and Dolophine® (methadone) — that the FDA considers to have exerted a “particular impact on the epidemic.” That information can be accessed [here].

The FDA appears to be under increasing pressure from Congress to do something about problems associated with opioid analgesics, especially overdoses and deaths that have been sensationalized in the news media. In a great many cases, reporters have focused unilaterally on tragic outcomes among persons who have misused or abused these medications in some way, without any equal balance on the millions of patients with pain who need opioid analgesics on a daily basis to thrive and survive, and are compliant with instructions for safe use of the drugs.

It is interesting that Dr. Hamburg places much emphasis on prescribers knowing and following information on FDA-approved product labeling — which is appropriate. However, the agency also is facing making a decision regarding a petition from last summer submitted by PROP (Physicians for Responsible Opioid Prescribing, most recently discussed in an UPDATE here) that would significantly change opioid-product labeling in terms of indication, dose, and duration of therapy.

Thus far, the FDA has exhibited admirable restraint in not leaping to judgments or making changes based on the weak, biased, or deficient evidence that is available to support the petition. Agency staff have patiently listened to testimony, gathered comments, and (we assume) are evaluating all input from objective, evidence-based perspectives.

Meanwhile, the new ER/LA-Opioid REMS — for extended-release and long-acting products — is still in a start-up phase, and the FDA is wise in giving that program a chance to take hold. Prescriber education is a critical component of the new REMS; although, as of this date (3/13/2013), few accredited programs are available and only one continuing education course was listed at the industry-supported website [here].

As for patient education, which is also deemed critical for reducing opioid-related problems, the selection of available materials is sparse. The patient counseling document mentioned in the FDA letter is brief, one page, and lists some essential “do and don’t” admonitions, but it does not provide a proper understanding of opioid risks and safe use, how to recognize adverse reactions or other problems, and being prepared for what to do in an emergency. For that sort of patient (and caregiver) education we recommend our Opioids911-Safety program available at Opioids911.org.

http://updates.pain-topics.org/2013/03/letter-from-us-fda-to-all-opioid.html